Shimojani
Shimojani LLC is a biotech company focused on developing therapies to reduce hemorrhage risk in acute ischemic stroke patients. They have licensed a novel invention from Niigata University that targets a key pathway involved in stroke severity, aiming to advance this work into clinical trials to improve survival and quality of life for stroke victims.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Licensed therapeutic program to reduce hemorrhagic conversion in acute ischemic stroke
An academic-origin therapeutic program licensed for development and commercialization aimed at reducing hemorrhagic conversion in acute ischemic stroke patients, including those treated with thrombolytic agents; program is in preclinical and IND-enabling development.
Licensed therapeutic program to reduce hemorrhagic conversion in acute ischemic stroke
An academic-origin therapeutic program licensed for development and commercialization aimed at reducing hemorrhagic conversion in acute ischemic stroke patients, including those treated with thrombolytic agents; program is in preclinical and IND-enabling development.
Services
Validation and advancement of therapeutic candidates from animal models toward IND-enabling studies, including biomarker analysis and coordination with clinical experts.
Validation and advancement of therapeutic candidates from animal models toward IND-enabling studies, including biomarker analysis and coordination with clinical experts.
Expertise Areas
- Acute ischemic stroke therapeutics
- Preclinical model development and validation
- IND-enabling development and regulatory strategy
- Biomarker-driven translational validation
Key Technologies
- Rodent ischemic stroke models
- Signal transduction pathway analysis
- Biomarker assays for pathway activation
- Small-molecule drug evaluation
News & Updates
Shimojani LLC has acquired an exclusive license from Niigata University for a potential stroke therapy that reduces hemorrhage risk, aiming to advance into clinical studies.
Shimojani LLC has acquired an exclusive license from Niigata University for a potential stroke therapy that reduces hemorrhage risk, aiming to advance into clinical studies.